Literature DB >> 12460302

Controversies in acral lentiginous melanoma.

Jennifer R Stalkup1, Ida F Orengo, Rajani Katta.   

Abstract

BACKGROUND: Acral lentiginous melanoma (ALM) is a subtype of melanoma initially described only two and half decades ago, but well-recognized by dermatologists today. However, several areas of controversy surround this entity.
OBJECTIVE: The primary aims of this article are to review the literature, highlight recent advances, and review some of the ongoing controversies in ALM.
METHODS: A review of the English language literature was performed.
RESULTS: Controversy continues to surround ALM, particularly in regard to diagnostic histologic and clinical criteria. This leads to difficulties when reviewing studies that evaluate the epidemiology, etiology, and prognosis of ALM.
CONCLUSION: Progress in understanding ALM requires the development of standardized diagnostic criteria.

Entities:  

Mesh:

Year:  2002        PMID: 12460302     DOI: 10.1046/j.1524-4725.2002.02082.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  9 in total

1.  [Operative therapy of acral melanomas].

Authors:  M Möhrle; V Lichte; H Breuninger
Journal:  Hautarzt       Date:  2011-05       Impact factor: 0.751

2.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Authors:  F Stephen Hodi; Christopher L Corless; Anita Giobbie-Hurder; Jonathan A Fletcher; Meijun Zhu; Adrian Marino-Enriquez; Philip Friedlander; Rene Gonzalez; Jeffrey S Weber; Thomas F Gajewski; Steven J O'Day; Kevin B Kim; Donald Lawrence; Keith T Flaherty; Jason J Luke; Frances A Collichio; Marc S Ernstoff; Michael C Heinrich; Carol Beadling; Katherine A Zukotynski; Jeffrey T Yap; Annick D Van den Abbeele; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

Review 3.  Melanocytic nevi simulant of melanoma with medicolegal relevance.

Authors:  Guido Massi
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.064

4.  Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.

Authors:  Katherine Zukotynski; Jeffrey T Yap; Anita Giobbie-Hurder; Jeffrey Weber; Rene Gonzalez; Thomas F Gajewski; Steven O'Day; Kevin Kim; F Stephen Hodi; Annick D Van den Abbeele
Journal:  Cancer Imaging       Date:  2014-11-12       Impact factor: 3.909

5.  Epidemiological and histopathological profile of malignant melanoma in Malawi.

Authors:  Maurice Mulenga; Nathan D Montgomery; Maganizo Chagomerana; Tenganawo Mzumala; Tamiwe Tomoka; Coxcilly Kampani; Yuri Fedoriw; Satish Gopal; Lisbet Sviland
Journal:  BMC Clin Pathol       Date:  2019-04-02

6.  The clinicopathological and gene expression patterns associated with ulceration of primary melanoma.

Authors:  Rosalyn Jewell; Faye Elliott; Jonathan Laye; Jérémie Nsengimana; John Davies; Christy Walker; Caroline Conway; Angana Mitra; Mark Harland; Martin G Cook; Andy Boon; Sarah Storr; Sabreena Safuan; Stewart G Martin; Karin Jirström; Håkan Olsson; Christian Ingvar; Martin Lauss; Tim Bishop; Göran Jönsson; Julia Newton-Bishop
Journal:  Pigment Cell Melanoma Res       Date:  2014-10-01       Impact factor: 4.693

Review 7.  More than just acral melanoma: the controversies of defining the disease.

Authors:  Sara S Bernardes; Ingrid Ferreira; David E Elder; Aretha B Nobre; Héctor Martínez-Said; David J Adams; Carla Daniela Robles-Espinoza; Patricia A Possik
Journal:  J Pathol Clin Res       Date:  2021-07-02

8.  Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature.

Authors:  Ivan R Bristow; Katharine Acland
Journal:  J Foot Ankle Res       Date:  2008-09-15       Impact factor: 2.303

9.  Acral lentiginous melanoma in situ: a diagnostic and management challenge.

Authors:  Hyun Sun Park; Kwang Hyun Cho
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.